Conference
Phase II trial of the multi-targeted antifolate LY231514 (MTA) as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC)
Authors
Rusthoven J; Eisenhauer E; Butts C; Gregg R; Dancey J; Fisher B; Iglesias J
Volume
33
Pagination
pp. 1045-1045
Publisher
PERGAMON-ELSEVIER SCIENCE LTD
Publication Date
September 1, 1997
Conference proceedings
EUROPEAN JOURNAL OF CANCER
ISSN
0959-8049